A Phase 2 Study of Alimta and Epirubicin Administered Every 21 Days in Patients With Locally Advanced or Metastatic Breast Cancer

CompletadoFase 2ClinicalTrials.gov

ID: NCT00097383Tipo: INTERVENTIONAL

Traducción no disponible, mostrando original

Resumen

This is a non-randomized Phase 2 portion of a study testing ALIMTA and epirubicin in combination for locally advanced or metastatic breast cancer. Epirubicin is a well-established drug for the therapy of breast cancer. Both ALIMTA and epirubicin have been combined with other drugs but they have not yet been combined with each other. It is expected that the patient will benefit from the different mechanisms of action of the two drugs.

Elegibilidad

Edad mínima: 18 YearsSexo: FEMALE

Criterios de inclusión

Diagnosis of locally advanced or metastatic breast cancer not amenable to local treatment.
Patients must be chemo-naive or have only neoadjuvant and/or adjuvant chemotherapy.
Patients must have at least one measurable lesion in an area not previously irradiated.
No chemotherapy at least 4 weeks prior to study enrollment.
Signed informed consent from patient.

Criterios de exclusión

Treatment with any drug within the last 30 days that has not received regulatory approval.
Serious systemic disorders, including active infection.
Significant cardiovascular disease.
Pregnancy or breast feeding.
Inability or unwillingness to take folic acid or Vitamin B12 supplementation.

Intervenciones

drug

ALIMTA plus Epirubicin

Ubicaciones

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.

La Plata, Buenos Aires, Argentina

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.

Rosario, Santa Fe Province, Argentina

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.

Buenos Aires, Argentina

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.

Ciudad de Buenos Aires, Argentina

Patrocinadores

PrincipalEli Lilly and Company

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Phase 2 Study of Alimta and Epirubicin Administered Eve... | EligiMed